Stabilizes HIF from degradation in the proteasome and increases endogenous production of erythropoietin by inhibiting HIF-1α prolyl hydroxylase (IC50 = 0.49 µM); investigated in clinical trial for treatment of patients with anemia associated with chronic kidney disease and/or end-stage renal disease.